JAHA: HDL anti-inflammatory function, cardiovascular disease and risk of death.

High-density lipoprotein (HDL) cholesterol was negatively associated with cardiovascular disease.
have anti-inflammatory properties in in-body HDL, but it is not clear whether this has a protective effect on inflammatory patients.
A recent study published in JAHA, a authoritative journal in the field of cardiovascular disease, measured HDL's ability to inhibit oxidizing LDL oxidation (i.e., HDL inflammation index; HII) 12 months after evaluating the nest-type case-control study of the INTERVENTION trial (JUPITER) of Rhysovastatin.
517 patients with cardiovascular disease and all-cause deaths were compared with 517 age- and gender-matched controls.
multivariable condition logistic regression was used to assess the association between HII and cardiovascular disease and all-cause deaths.
median baseline HII is 0.54 (the four-digit range is 0.50-0.59).
12 months of treatment, the average HII decreased by 5.3% (95% CI was -8.9% to -1.7%; P - 0.005), while the placebo group decreased by 1.3% (95% CI was -6.5% to 4.0%; P-0.63) (Intergroup difference P-0.22).
hiI has a nonlinear relationship with cardiovascular disease and all-cause deaths.
The risk of cardiovascular disease/death increased significantly (adjusted risk ratio of 1.53; 95% CI was 1.06-2.21; P?0.02) compared to the reference group with the lowest incidence of the event (HII was 0.5-1.0).
addition, there is a significant interaction between the number of HDL particles and HII (P-0.002), so that more HDL particles can reduce the risk of events only when HDL is anti-inflammatory.
among JUPITER participants recruited on the basis of chronic inflammation, HII was associated with cardiovascular disease/mortality, with an optimal anti-inflammatory HII range of 0.5 to 1.0.
nonlinear relationship between HDL anti-inflammatory function and cardiovascular disease/death risk may partly explain the HDL paradox.
.